SCHEMBL1370385

SCHEMBL1370385

CON(C)C(=O)[C@H](C)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.49
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
FAAH O00519 1/20 0.46
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ACHE P22303 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1370386 1.00 HPGD (0.49) HPGDKMT2AMEN1FAAHNPC1
SCHEMBL24332207 1.00 HPGD (0.49) HPGDKMT2AMEN1FAAHNPC1
SCHEMBL17046807 0.89 MEN1 (0.50) HPGDKMT2AMEN1FAAHNPC1
SCHEMBL17046806 0.89 MEN1 (0.50) HPGDKMT2AMEN1FAAHNPC1
SCHEMBL532254 0.89 MEN1 (0.50) HPGDKMT2AMEN1FAAHNPC1
SCHEMBL9328469 0.85 HPGD (0.47) HPGDKMT2AMEN1FAAHNPC1
SCHEMBL841890 0.82 HPGD (0.43) HPGDKMT2AMEN1FAAHNPC1
SCHEMBL9329177 0.82 HPGD (0.50) HPGDFAAHNPC1RAB9ACA12
SCHEMBL841889 0.82 HPGD (0.43) HPGDKMT2AMEN1FAAHNPC1
SCHEMBL842052 0.80 EPOR (0.41) HPGDKMT2AMEN1FAAHNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3377474-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-08-16 EP disclosed
EP-3377474-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-08-16 EP disclosed
CN-109219596-B Macrocyclic broad spectrum antibiotics 阿奇克斯制药公司 2022-04-19 CN disclosed
US-11072635-B2 Macrocyclic broad spectrum antibiotics RQX PHARMACEUTICALS, INC. (US) 2021-07-27 US disclosed
US-11072635-B2 Macrocyclic broad spectrum antibiotics RQX PHARMACEUTICALS, INC. (US) 2021-07-27 US disclosed
US-20200239519-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. 2020-07-30 US disclosed
US-20200239519-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. 2020-07-30 US disclosed
US-20140309275-A1 Sphingosine Analogs, Compositions, and Methods Related Thereto UNIV EMORY (US) 2014-10-16 US disclosed
US-20140155376-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2014-06-05 US disclosed
US-20140155376-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2014-06-05 US disclosed
US-20140155376-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2014-06-05 US disclosed
EP-2571880-A1 PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-03-27 EP disclosed
WO-2011144585-A1 PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-11-24 WO disclosed
WO-2011144585-A1 PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-11-24 WO disclosed
US-20110288067-A1 Pyrrolopyrazine Kinase Inhibitors HENDRICKS ROBERT THAN (US) 2011-11-24 US disclosed
US-20110288067-A1 Pyrrolopyrazine Kinase Inhibitors HENDRICKS ROBERT THAN (US) 2011-11-24 US disclosed
US-20110288067-A1 Pyrrolopyrazine Kinase Inhibitors HENDRICKS ROBERT THAN (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288067-A1 Pyrrolopyrazine Kinase Inhibitors SYK, ZAP70, JAK2 HPGD 3393/4885KMT2A 1286/4885MEN1 3977/4885
US-20140155376-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK2 HPGD 3393/4885KMT2A 1286/4885MEN1 3977/4885
US-20200239519-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC HPGD 4261/4885KMT2A 3283/4885MEN1 2531/4885
US-11072635-B2 Macrocyclic broad spectrum antibiotics MRPL21, PEPD, CTSC HPGD 4261/4885KMT2A 3283/4885MEN1 2531/4885
US-20140309275-A1 Sphingosine Analogs, Compositions, and Methods Related Thereto SPHK1, S1PR1, S1PR2 HPGD 2735/4885KMT2A 584/4885MEN1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.